Traws Pharma (0T20) Income Statement
Traws Pharma Income Statement
Last quarter (Q2 2026), Traws Pharma's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q2, Traws Pharma's net income was $-3.05M. See Traws Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 2.79M | $ 226.00K | $ 226.00K | $ 226.00K | $ 226.00K | |
| $ 2.79M | $ 214.00K | $ 226.00K | $ 226.00K | $ 226.00K | |
| $ 20.66M | $ 49.56M | $ 20.52M | $ 19.85M | $ 16.72M | |
| Depreciation and Amortization | $ 61.00K | $ 12.00K | $ 16.00K | $ 14.00K | $ 14.00K |
| $ -17.81M | $ -166.51M | $ -20.28M | $ -19.61M | $ -16.48M | |
| $ -17.88M | $ -49.35M | $ -20.30M | $ -19.63M | $ -16.50M | |
| $ 27.05M | $ -117.17M | $ 1.35M | $ 663.00K | $ 333.00K | |
| $ 9.17M | $ -166.52M | $ -18.95M | $ -18.96M | $ -16.16M | |
| $ 9.17M | $ -54.67M | $ -18.95M | $ -18.96M | $ -16.16M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.83 | $ -35.21 | $ -22.57 | $ -22.68 | $ -24.01 |
| Diluted EPS | $ 0.82 | $ -35.21 | $ -22.57 | $ -22.68 | $ -24.01 |
| Weighted Average Shares Outstanding | 8.23M | 1.55M | 839.55K | 836.33K | 673.29K |
| Weighted Average Shares Outstanding (Diluted) | 8.38M | 1.55M | 839.55K | 836.33K | 673.29K |
Currency in USD